Literature DB >> 25645927

HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.

Nancy Yu1, Michael Kakunda1, Victoria Pham2, Jennie R Lill2, Pan Du3, Matthew Wongchenko4, Yibing Yan4, Ron Firestein5, XiaoDong Huang6.   

Abstract

The Wnt/β-catenin pathway causes accumulation of β-catenin in the cytoplasm and its subsequent translocation into the nucleus to initiate the transcription of the target genes. Without Wnt stimulation, β-catenin forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), casein kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β) and undergoes phosphorylation-dependent ubiquitination. Phosphatases, such as protein phosphatase 2A (PP2A), interestingly, also are components of this degradation complex; therefore, a balance must be reached between phosphorylation and dephosphorylation. How this balance is regulated is largely unknown. Here we show that a heat shock protein, HSP105, is a previously unidentified component of the β-catenin degradation complex. HSP105 is required for Wnt signaling, since depletion of HSP105 compromises β-catenin accumulation and target gene transcription upon Wnt stimulation. Mechanistically, HSP105 depletion disrupts the integration of PP2A into the β-catenin degradation complex, favoring the hyperphosphorylation and degradation of β-catenin. HSP105 is overexpressed in many types of tumors, correlating with increased nuclear β-catenin protein levels and Wnt target gene upregulation. Furthermore, overexpression of HSP105 is a prognostic biomarker that correlates with poor overall survival in breast cancer patients as well as melanoma patients participating in the BRIM2 clinical study.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645927      PMCID: PMC4372692          DOI: 10.1128/MCB.01307-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

Review 1.  Immunohistochemical changes in prostate cancer after androgen deprivation therapy.

Authors:  D G Bostwick
Journal:  Mol Urol       Date:  2000

Review 2.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

3.  Heat shock protein expression independently predicts clinical outcome in prostate cancer.

Authors:  P A Cornford; A R Dodson; K F Parsons; A D Desmond; A Woolfenden; M Fordham; J P Neoptolemos; Y Ke; C S Foster
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits".

Authors:  A J Rowan; H Lamlum; M Ilyas; J Wheeler; J Straub; A Papadopoulou; D Bicknell; W F Bodmer; I P Tomlinson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival.

Authors:  K L King; A F Li; G Y Chau; C W Chi; C W Wu; C L Huang; W Y Lui
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

7.  Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling.

Authors:  XiaoDong Huang; James C McGann; Bob Y Liu; Rami N Hannoush; Jennie R Lill; Victoria Pham; Kim Newton; Michael Kakunda; Jinfeng Liu; Christine Yu; Sarah G Hymowitz; Jo-Anne Hongo; Anthony Wynshaw-Boris; Paul Polakis; Richard M Harland; Vishva M Dixit
Journal:  Science       Date:  2013-01-31       Impact factor: 47.728

8.  A gene-expression signature as a predictor of survival in breast cancer.

Authors:  Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

Authors:  Mercedes E Gorre; Katharine Ellwood-Yen; Gabriela Chiosis; Neal Rosen; Charles L Sawyers
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

10.  Heat shock protein 105 is overexpressed in a variety of human tumors.

Authors:  Mikio Kai; Tetsuya Nakatsura; Hiroshi Egami; Satoru Senju; Yasuharu Nishimura; Michio Ogawa
Journal:  Oncol Rep       Date:  2003 Nov-Dec       Impact factor: 3.906

View more
  16 in total

1.  Cortical astroglia undergo transcriptomic dysregulation in the G93A SOD1 ALS mouse model.

Authors:  Sean J Miller; Jenna C Glatzer; Yi-Chun Hsieh; Jeffrey D Rothstein
Journal:  J Neurogenet       Date:  2018-11-06       Impact factor: 1.250

2.  HSP110 promotes colorectal cancer growth through STAT3 activation.

Authors:  K Berthenet; A'dem Bokhari; A Lagrange; G Marcion; C Boudesco; S Causse; A De Thonel; M Svrcek; A R Goloudina; S Dumont; A Hammann; D S Biard; O N Demidov; R Seigneuric; A Duval; A Collura; G Jego; C Garrido
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

3.  Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.

Authors:  Gustavo J Gozzi; Daniel Gonzalez; Christophe Boudesco; Alexandre M M Dias; Guillaume Gotthard; Burhan Uyanik; Lucile Dondaine; Guillaume Marcion; François Hermetet; Camille Denis; Laurianne Hardy; Peggy Suzanne; Romain Douhard; Gaetan Jego; Laurence Dubrez; Oleg N Demidov; Fabrice Neiers; Loïc Briand; Jana Sopková-de Oliveira Santos; Anne-Sophie Voisin-Chiret; Carmen Garrido
Journal:  Cell Death Differ       Date:  2019-05-08       Impact factor: 15.828

4.  Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.

Authors:  Maria Chiara Proto; Donatella Fiore; Chiara Piscopo; Silvia Franceschelli; Valentina Bizzarro; Chiara Laezza; Gianluigi Lauro; Alessandra Feoli; Alessandra Tosco; Giuseppe Bifulco; Gianluca Sbardella; Maurizio Bifulco; Patrizia Gazzerro
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 5.  Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.

Authors:  Suman Chatterjee; Timothy F Burns
Journal:  Int J Mol Sci       Date:  2017-09-15       Impact factor: 5.923

6.  Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes.

Authors:  Peiman Shooshtarizadeh; Anne Helness; Charles Vadnais; Nelleke Brouwer; Hugues Beauchemin; Riyan Chen; Halil Bagci; Frank J T Staal; Jean-François Coté; Tarik Möröy
Journal:  Nat Commun       Date:  2019-03-20       Impact factor: 14.919

7.  A Non-enveloped Virus Hijacks Host Disaggregation Machinery to Translocate across the Endoplasmic Reticulum Membrane.

Authors:  Madhu Sudhan Ravindran; Parikshit Bagchi; Takamasa Inoue; Billy Tsai
Journal:  PLoS Pathog       Date:  2015-08-05       Impact factor: 6.823

Review 8.  Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications.

Authors:  Daming Zuo; John Subjeck; Xiang-Yang Wang
Journal:  Front Immunol       Date:  2016-03-01       Impact factor: 7.561

Review 9.  Molecular regulation and pharmacological targeting of the β-catenin destruction complex.

Authors:  Eline C van Kappel; Madelon M Maurice
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 10.  The regulation of β-catenin activity and function in cancer: therapeutic opportunities.

Authors:  Shuang Shang; Fang Hua; Zhuo-Wei Hu
Journal:  Oncotarget       Date:  2017-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.